Back To Search Results

Migraine Prophylaxis

Editor: Renu Kadian Updated: 8/28/2023 10:14:40 PM

Introduction

Recurrent migraines can be functionally disabling and can impair quality of life. The disabling nature of migraine headaches leads to frequent visits to outpatient clinics and emergency department facilities, causing significant health and financial burdens. Headaches fall in the top five causes of emergency department visits and the top twenty reasons for outpatient visits.[1] The overall prevalence of migraine headaches is estimated to be 16%; they are more frequent in women, with a sex prevalence ratio of 3:1.[1] Around 38% of patients with episodic migraines would benefit from prophylactic treatment, but only 3% to 13% get it.[2]

After treating acute migraines, all migraine patients should be evaluated for preventive therapy. The purpose of preventive therapy is to decrease the frequency, severity, and duration of migraine attacks. Furthermore, preventative therapy can increase responsiveness to acute migraine therapy and improve the quality of life.

Prophylactic treatment is not curative, and most patients will still need abortive medications for acute migraine. Before starting prophylactic medications, it is imperative to evaluate if patients are using proper and adequate abortive therapies. Overuse of abortive medications can cause rebound headaches.[2][3]

Function

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Function

Approximately 28 million Americans older than 12 suffer from migraine headaches. Around 18% of women and 6% of men in the United States suffer from migraine headaches. About 38% of those with a migraine headache need to be on preventive therapy, whereas only 3% to 13% of migraine sufferers use preventative treatment.[2][3]

Prophylactic migraine treatment should be considered in patients with more than three monthly episodes or at least eight headache days in one month.[4][5] Patients with severe debilitating headaches despite appropriate acute treatment or those who are intolerant or have contraindications to acute therapy. Prophylaxis should also be considered in patients with medication overuse headaches, certain migraine subtypes like hemiplegic migraine, basilar migraine, migraine with prolonged aura, or if the patient prefers.[2][3][4]

Prophylactic Treatment for Migraine Headache

It is important to determine the frequency, duration, and severity of headaches and any triggers that may precipitate them. All patients with migraine headaches should maintain a headache diary to determine the frequency, severity, and duration of headaches. It also helps identify any triggers that can cause a migraine headache. Some common triggers include environmental factors such as noise, odor, medications (like oral contraceptive pills, hormone replacement therapy, and H2-receptor blockers), food (cheese, wine, chocolate), and behavioral factors such as sleep deficit or excessive sleep.[6] Preventive drug therapy may not be needed if triggers can be identified and modified.[7]

1. Pharmacological Therapies for Migraine Prevention

Various medications are available for migraine prophylaxis and prevention. Choosing the right agent is essential. The efficacy, side effects, contraindications, cost, and compliance should be considered when deciding on the right agent. It is also crucial to consider comorbid medical conditions and drug interactions. Efficacy of treatment can be assessed only after a 2 to 3-month trial; a full trial may take up to 6 months. Always start at a low dose and titrate up slowly. Monotherapy is preferred as there are no significant benefits of using more than one drug unless indicated for other comorbid conditions. Patients should be re-evaluated, and medications preferably discontinued after one year, even if they show improvement in symptoms. Successful therapy is defined as a reduction of migraine attacks by at least 50%.[3][4][8]

Migraine attacks are associated with neuronal activation, which is thought to be due to cortical spreading activation (CSD) or a brainstem generator. Preventive medications inhibit CSD through various mechanisms, such as blocking calcium and sodium channels, blocking gap junctions, and inhibiting matrix metalloproteinases.[9][10]

  • Beta-blockers

Propranolol is the most common and one of the most effective first-line medications used for migraine prophylaxis.[11] The starting dose is 40 mg and can go up to 320 mg daily. It may take up to 12 weeks at an adequate dose for therapeutic benefits to become apparent.

Other beta-blockers that can be used are timolol, atenolol, and metoprolol.[12] They should be considered in patients with underlying cardiovascular disease. Common side effects of this group of medications are fatigue, nausea, dizziness, decreased exercise tolerance, and depression. Contraindications include severe asthma, peripheral vascular disease, severe bradycardia, and heart blocks.[3][13]

  • Anticonvulsants

Depakote and sodium valproate are two anticonvulsant drugs used for migraine prophylaxis.[14] They are among the first-line agents used for migraine prevention. They are particularly useful for prolonged and atypical migraines. Common side effects include nausea, drowsiness, hair loss, tremors, and hyperammonemia. They are contraindicated in patients with severe liver disease and pancreatitis. Sodium valproate cannot be used in pregnancy because of teratogenicity.

Topamax is another drug used as a first-line treatment option for migraine prophylaxis.[15] Topamax has comparable efficacy to propranolol for preventing migraine headaches. It should be started at a low dose of 25 mg daily and slowly titrated up to 100 mg twice daily. Patients should continue treatment for at least 2 to 3 months before the treatment efficacy is evaluated. Common side effects include memory and concentration problems, paresthesia, fatigue, nausea, and anorexia. Topamax can cause metabolic acidosis and precipitate kidney stones, acute myopia, and angle-closure glaucoma.

Gabapentin has little efficacy for migraine prevention. The recommended dose is from 1200 to 2400 mg per day. Common side effects include somnolence and dizziness.[16][17][18]

  • Antidepressants

Amitriptyline is shown to be beneficial in migraine prevention.[19] It may be more effective than propranolol in mixed migraine-tension types of headaches. Response to treatment can be seen in up to 4 weeks and is more rapid than with beta-blockers. The daily dosing is 25 to 150 mg daily.

Another antidepressant that is probably effective in migraine prevention is venlafaxine.[20] It is probably as effective as amitriptyline. The dose used is 150 mg daily. Fluoxetine has also been used for migraine prophylaxis. Common side effects include weight gain, drowsiness, dry mouth, and urinary retention. Contraindicated in concurrent use with monoamine oxidase inhibitors (MAOIs).[3][13][19]

  • Calcium-channel Blockers

The efficacy of calcium channel blockers in the preventive treatment of migraine is weak. Verapamil has shown weak efficacy in preventing migraines. It is used as one of the second-line pharmacological options for migraine prophylaxis.

Flunarizine is a nonspecific calcium channel blocker that has shown evidence of some efficacy. It is not available in the United States.[3][13]

  • Angiotensin Blockers: ACE-Is/ARBs

Lisinopril and candesartan have shown some weak efficacy for migraine prevention.[21][22][13]

  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)

They are used for the prevention of menstrual migraine. Start treatment a few days before the anticipated start of the menstrual cycle and continue for the first few days.[23]

  • Triptans

Zolmitriptan, frovatriptan, and naratriptan have shown benefits in the short-term prevention of menstrual-related migraines. They are started several days before the expected onset and continued for 5 to 6 days.[24][23]

  • Calcitonin Gene-related Peptide Therapy

U.S. FDA approved Erenumab for the treatment of migraine prevention in May 2018. It is a monoclonal antibody that mediates the transmission of migraine pain by binding to the calcitonin gene-related peptide receptor. It comes as a monthly subcutaneous injection. Common side effects include injection site reaction, constipation, and cramps.[3][25]

  • Others

Some other medications that have some but little efficacy for migraine prevention include magnesium, vitamin B2, coenzyme Q10, and botulinum toxin.[26][27] The benefits of botulinum toxin A have not been statistically proven for treating an episodic migraine headache; however, it is proven effective for treating chronic headaches.

Methysergide and phenelzine are used as last resort for severe and refractory cases. Use for more than six months can cause cardiac and retroperitoneal fibrosis.[27][28]

  • Alternative Therapies

Butterbur and feverfew are two herbal medications available for use for migraine prophylaxis. Studies have failed to prove any substantial benefit with feverfew. Butterbur extract made from underground parts of the plant has been endorsed by the American Academy of Neurology and the American Headache Society to reduce the frequency of migraines.[3][27] Although the American Academy of Neurology withdrew its 2012 recommendation on complementary therapy due to serious safety concerns around butterbur, the Canadian Headache Society continues to strongly recommend its use.[29]

2. Non-pharmacological Therapies

Identifying and modifying the trigger, if possible, is important. It is helpful to maintain headache diaries to identify triggers and follow responses when triggers become modified. Therapies that can help prevent migraines include relaxation, acupuncture, massage, cognitive behavior therapy, and biofeedback techniques.[3][30] The FDA approved a transcutaneous electrical nerve stimulation (TENS) device in March 2014 for migraine prevention. More studies are needed to determine its long-term efficacy.[13][30]

2012 AHS/AAN Guidelines for Migraine Prevention in Adults

Medications are Divided into Three Groups

  • Level A (medications that have proven effectiveness and should be offered to patients who require migraine prophylaxis): Sodium valproate, valproic acid, 
  • Level B (medications that are probably effective and should be considered for migraine prevention): Amitriptyline, naproxen, fenoprofen, ketoprofen, ibuprofen, magnesium, atenolol, venlafaxine, riboflavin, histamine.
  • Level C (medications with possible effectiveness and may be considered for migraine prevention): Candesartan, carbamazepine, lisinopril, pindolol, nebivolol, clonidine, cyproheptadine, coenzyme Q10.[31]

The following is a list of medications as per the current guidance for migraine prophylaxis:

First-line agents (established efficacy based on evidence):

  • Divalproex
  • Propranolol
  • Timolol
  • Topiramate
  • Frovatriptan
  • Metoprolol

Second-line agents (probably established efficacy based on evidence):

  • Amitriptyline
  • Atenolol
  • Nadolol
  • Naratriptan
  • venlafaxine
  • Zolmitriptan

Other medications (less evidence-based) for episodic migraine prevention:

Possibly Effective

  • Candesartan
  • Carbamazepine
  • Lisinopril
  • Nebivolol
  • Nicardipine

Conflicting or Inadequate Data to Support or Refute the Use

  • Bisoprolol
  • Fluoxetine
  • Gabapentin
  • Nifedipine
  • Nimodipine
  • Pindolol
  • Protriptyline
  • Verapamil

Ineffective

  • Acebutolol
  • Lamotrigine
  • Oxcarbazepine
  • Telmisartan

Issues of Concern

Migraine Prophylaxis in Children

Propranolol is commonly prescribed for migraine preventive treatment in children, although studies have shown conflicting results. Similarly, topiramate is commonly prescribed for children, but its efficacy is questionable.

Data is insufficient for other medications like cyproheptadine, amitriptyline, and valproic acid. Flunarizine is believed to be effective for preventing migraines in children but is not available in the United States.[3][1][32]

Migraine Prophylaxis in Pregnancy

It is imperative to maintain a cautious approach. Risks and benefits should be discussed with the patient in detail. Labetalol at a dose of 150 mg twice per day has shown some benefit in pregnant women. Propranolol, topiramate, amitriptyline, fluoxetine, and gabapentin are pregnancy category C drugs. Valproic acid is teratogenic and contraindicated, and the use of lisinopril and candesartan is not recommended for pregnant women.[33]

Clinical Significance

Recurrent migraines are often functionally disabling and can impair quality of life. Prophylactic therapy may decrease the frequency, severity, and duration of migraine attacks, increase responsiveness to acute migraine therapy and improve quality of life. Migraines are different from other headaches by the following attributes:

  • Lasting 4 to 72 hours
  • Unilateral location
  • Pulsating quality
  • Moderate to severe intensity
  • Aggravated by physical activity
  • Associations with nausea, vomiting, phonophobia, or photophobia

Migraine headaches may have an aural phase before the onset of the headache.[34] Chronic and episodic migraines fall in a spectrum of migraine disorders; however, they are distinct clinical entities.[35] Chronic migraine is uncommon (found in 1 to 5% of patients with migraine) and is defined as a headache lasting 15 times a month or more for at least three months.[34] Patients with chronic migraine have a poor quality of life.[35] Prophylaxis for episodic migraine may reduce headache severity and frequency and prevent progression to chronic migraine.

Other Issues

Once the need for prophylaxis is established, the following consensus-based principles of care should be adhered to improve the success of prophylactic treatment:

  • Start medications with the highest evidence-based effectiveness.
  • Avoid agents that may exacerbate comorbid conditions.[31]
  • Begin with the lowest effective dose and increase every two to four weeks to achieve the therapeutic effect and stop if the patient develops adverse effects.
  • Successful treatment is described as a 50% reduction in the episodes of headaches or days, a significant shortening of episode duration, or an increase in response to acute therapy.
  • If headaches are under control for at least 6 to 12 months, therapy should be slowly tapered and discontinued.[4]

Enhancing Healthcare Team Outcomes

Migraine management requires the efforts of an interprofessional healthcare team that includes clinicians, nurses, and pharmacists. When the clinician decides to implement migraine prophylaxis, the pharmacist should perform medication reconciliation and be available to recommend potential agents. The nurse can counsel the patient on administration and serve as a liaison between the prescriber and other healthcare team members. This interprofessional approach will yield optimal patient outcomes with the fewest adverse events. [Level 5]

Around 18% of women and 6% of men in the United States suffer from migraine headaches, with an estimated total prevalence of around 16%. It is a common cause of emergency department and clinic visits and causes significant financial and health burdens. Less than 13% of migraine patients are believed to be on prophylactic therapy, whereas it is estimated that around 38% of episodic migraine patients would actually benefit from prophylactic therapy. It is important to educate all headache patients about identifying their headache type and frequency. Simple strategies like maintaining a headache diary to help identify the frequency, severity, and triggers of headaches can help identify patients needing prophylactic treatment.[2][3]

References


[1]

Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache. 2013 Mar:53(3):427-36. doi: 10.1111/head.12074. Epub 2013 Mar 7     [PubMed PMID: 23470015]


[2]

Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 Jan 30:68(5):343-9     [PubMed PMID: 17261680]


[3]

Ha H, Gonzalez A. Migraine Headache Prophylaxis. American family physician. 2019 Jan 1:99(1):17-24     [PubMed PMID: 30600979]


[4]

Silberstein SD. Preventive Migraine Treatment. Continuum (Minneapolis, Minn.). 2015 Aug:21(4 Headache):973-89. doi: 10.1212/CON.0000000000000199. Epub     [PubMed PMID: 26252585]


[5]

Parikh SK, Silberstein SD. Preventive Treatment for Episodic Migraine. Neurologic clinics. 2019 Nov:37(4):753-770. doi: 10.1016/j.ncl.2019.07.004. Epub 2019 Aug 22     [PubMed PMID: 31563231]


[6]

Finocchi C, Sivori G. Food as trigger and aggravating factor of migraine. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2012 May:33 Suppl 1():S77-80. doi: 10.1007/s10072-012-1046-5. Epub     [PubMed PMID: 22644176]


[7]

Peroutka SJ. What turns on a migraine? A systematic review of migraine precipitating factors. Current pain and headache reports. 2014 Oct:18(10):454. doi: 10.1007/s11916-014-0454-z. Epub     [PubMed PMID: 25160711]

Level 1 (high-level) evidence

[8]

Starling AJ, Dodick DW. Best practices for patients with chronic migraine: burden, diagnosis, and management in primary care. Mayo Clinic proceedings. 2015 Mar:90(3):408-14. doi: 10.1016/j.mayocp.2015.01.010. Epub     [PubMed PMID: 25744118]


[9]

Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain. Pain. 2013 Dec:154 Suppl 1():. doi: 10.1016/j.pain.2013.07.021. Epub     [PubMed PMID: 24347803]


[10]

Spierings EL. Mechanism of migraine and action of antimigraine medications. The Medical clinics of North America. 2001 Jul:85(4):943-58, vi-vii     [PubMed PMID: 11480266]


[11]

Modi S, Lowder DM. Medications for migraine prophylaxis. American family physician. 2006 Jan 1:73(1):72-8     [PubMed PMID: 16417067]


[12]

Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, Sehgal N, Kuester J. A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache. PloS one. 2015:10(7):e0130733. doi: 10.1371/journal.pone.0130733. Epub 2015 Jul 14     [PubMed PMID: 26172390]

Level 1 (high-level) evidence

[13]

Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24:78(17):1337-45. doi: 10.1212/WNL.0b013e3182535d20. Epub     [PubMed PMID: 22529202]

Level 1 (high-level) evidence

[14]

Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S, Mathew N, Winner PK, Deaton R, Sommerville K, Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002 Jun 11:58(11):1652-9     [PubMed PMID: 12058094]

Level 1 (high-level) evidence

[15]

Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, Biondi D, Greenberg SJ, Hulihan J, CAPSS-277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clinical therapeutics. 2009 Mar:31(3):542-59. doi: 10.1016/j.clinthera.2009.03.020. Epub     [PubMed PMID: 19393844]

Level 1 (high-level) evidence

[16]

Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. The Cochrane database of systematic reviews. 2013 Jun 24:2013(6):CD010611. doi: 10.1002/14651858.CD010611. Epub 2013 Jun 24     [PubMed PMID: 23797677]

Level 1 (high-level) evidence

[17]

Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults. The Cochrane database of systematic reviews. 2013 Jun 24:2013(6):CD010610. doi: 10.1002/14651858.CD010610. Epub 2013 Jun 24     [PubMed PMID: 23797676]

Level 1 (high-level) evidence

[18]

Linde M,Mulleners WM,Chronicle EP,McCrory DC, Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. The Cochrane database of systematic reviews. 2013 Jun 24     [PubMed PMID: 23797675]

Level 1 (high-level) evidence

[19]

Xu XM, Liu Y, Dong MX, Zou DZ, Wei YD. Tricyclic antidepressants for preventing migraine in adults. Medicine. 2017 Jun:96(22):e6989. doi: 10.1097/MD.0000000000006989. Epub     [PubMed PMID: 28562550]


[20]

Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clinical neurology and neurosurgery. 2004 Dec:107(1):44-8     [PubMed PMID: 15567552]

Level 1 (high-level) evidence

[21]

Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ (Clinical research ed.). 2001 Jan 6:322(7277):19-22     [PubMed PMID: 11141144]

Level 1 (high-level) evidence

[22]

Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003 Jan 1:289(1):65-9     [PubMed PMID: 12503978]

Level 1 (high-level) evidence

[23]

Silberstein S, Patel S. Menstrual migraine: an updated review on hormonal causes, prophylaxis and treatment. Expert opinion on pharmacotherapy. 2014 Oct:15(14):2063-70. doi: 10.1517/14656566.2014.947959. Epub 2014 Aug 6     [PubMed PMID: 25100506]

Level 3 (low-level) evidence

[24]

Maasumi K, Tepper SJ, Kriegler JS. Menstrual Migraine and Treatment Options: Review. Headache. 2017 Feb:57(2):194-208. doi: 10.1111/head.12978. Epub 2016 Dec 2     [PubMed PMID: 27910087]


[25]

Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. A Controlled Trial of Erenumab for Episodic Migraine. The New England journal of medicine. 2017 Nov 30:377(22):2123-2132. doi: 10.1056/NEJMoa1705848. Epub     [PubMed PMID: 29171821]


[26]

von Luckner A, Riederer F. Magnesium in Migraine Prophylaxis-Is There an Evidence-Based Rationale? A Systematic Review. Headache. 2018 Feb:58(2):199-209. doi: 10.1111/head.13217. Epub 2017 Nov 13     [PubMed PMID: 29131326]

Level 1 (high-level) evidence

[27]

Rajapakse T, Pringsheim T. Nutraceuticals in Migraine: A Summary of Existing Guidelines for Use. Headache. 2016 Apr:56(4):808-16. doi: 10.1111/head.12789. Epub 2016 Mar 7     [PubMed PMID: 26954394]


[28]

Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J, Karp BP, Naumann M, So YT, Yablon SA. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 May 10:86(19):1818-26. doi: 10.1212/WNL.0000000000002560. Epub 2016 Apr 18     [PubMed PMID: 27164716]

Level 1 (high-level) evidence

[29]

Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E, Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24:78(17):1346-53. doi: 10.1212/WNL.0b013e3182535d0c. Epub     [PubMed PMID: 22529203]

Level 2 (mid-level) evidence

[30]

Schwedt TJ, Vargas B. Neurostimulation for Treatment of Migraine and Cluster Headache. Pain medicine (Malden, Mass.). 2015 Sep:16(9):1827-34. doi: 10.1111/pme.12792. Epub 2015 Jul 14     [PubMed PMID: 26177612]


[31]

Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012 Jun:52(6):930-45. doi: 10.1111/j.1526-4610.2012.02185.x. Epub     [PubMed PMID: 22671714]

Level 1 (high-level) evidence

[32]

Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S, American Academy of Neurology Quality Standards Subcommittee, Practice Committee of the Child Neurology Society. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology. 2004 Dec 28:63(12):2215-24     [PubMed PMID: 15623677]

Level 2 (mid-level) evidence

[33]

Silberstein SD. Headaches in pregnancy. The journal of headache and pain. 2005 Sep:6(4):172-4     [PubMed PMID: 16362655]


[34]

. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia : an international journal of headache. 2018 Jan:38(1):1-211. doi: 10.1177/0333102417738202. Epub     [PubMed PMID: 29368949]


[35]

Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Current pain and headache reports. 2012 Feb:16(1):86-92. doi: 10.1007/s11916-011-0233-z. Epub     [PubMed PMID: 22083262]